NASDAQ:ANTX - Nasdaq - US0373261058 - Common Stock - Currency: USD
Taking everything into account, ANTX scores 2 out of 10 in our fundamental rating. ANTX was compared to 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ANTX as it has an excellent financial health rating, but there are worries on the profitability. ANTX is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -55.76% | ||
ROE | -61.85% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -2.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.68 | ||
Quick Ratio | 8.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.07
-0.06 (-5.31%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.44 | ||
P/tB | 0.44 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -55.76% | ||
ROE | -61.85% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 8.68 | ||
Quick Ratio | 8.68 | ||
Altman-Z | -2.34 |